Transfer learning is a machine learning approach that reuses a learning method developed for a task as the starting point for a model on a target task. The goal of transfer learning is to improve performance of target learners by transferring the knowledge contained in other (but related) source domains. As a result, the need for large numbers of target-domain data is lowered for constructing target learners. Due to this immense property, transfer learning techniques are frequently used in ultrasound breast cancer image analyses. In this review, we focus on transfer learning methods applied on ultrasound breast image classification and detection from the perspective of transfer learning approaches, pre-processing, pre-training models, and convolutional neural network (CNN) models. Finally, comparison of different works is carried out, and challenges—as well as outlooks—are discussed.
Breast cancer diagnosis is one of the many areas that has taken advantage of artificial intelligence to achieve better performance, despite the fact that the availability of a large medical image dataset remains a challenge. Transfer learning (TL) is a phenomenon that enables deep learning algorithms to overcome the issue of shortage of training data in constructing an efficient model by transferring knowledge from a given source task to a target task. However, in most cases, ImageNet (natural images) pre-trained models that do not include medical images, are utilized for transfer learning to medical images. Considering the utilization of microscopic cancer cell line images that can be acquired in large amount, we argue that learning from both natural and medical datasets improves performance in ultrasound breast cancer image classification. The proposed multistage transfer learning (MSTL) algorithm was implemented using three pre-trained models: EfficientNetB2, InceptionV3, and ResNet50 with three optimizers: Adam, Adagrad, and stochastic gradient de-scent (SGD). Dataset sizes of 20,400 cancer cell images, 200 ultrasound images from Mendeley and 400 ultrasound images from the MT-Small-Dataset were used. ResNet50-Adagrad-based MSTL achieved a test accuracy of 99 ± 0.612% on the Mendeley dataset and 98.7 ± 1.1% on the MT-Small-Dataset, averaging over 5-fold cross validation. A p-value of 0.01191 was achieved when comparing MSTL against ImageNet based TL for the Mendeley dataset. The result is a significant improvement in the performance of artificial intelligence methods for ultrasound breast cancer classification compared to state-of-the-art methods and could remarkably improve the early diagnosis of breast cancer in young women.
Despite great achievements in classifying mammographic breast-mass images via deep-learning (DL), obtaining large amounts of training data and ensuring generalizations across different datasets with robust and well-optimized algorithms remain a challenge. ImageNet-based transfer learning (TL) and patch classifiers have been utilized to address these challenges. However, researchers have been unable to achieve the desired performance for DL to be used as a standalone tool. In this study, we propose a novel multi-stage TL from ImageNet and cancer cell line image pre-trained models to classify mammographic breast masses as either benign or malignant. We trained our model on three public datasets: Digital Database for Screening Mammography (DDSM), INbreast, and Mammographic Image Analysis Society (MIAS). In addition, a mixed dataset of the images from these three datasets was used to train the model. We obtained an average five-fold cross validation AUC of 1, 0.9994, 0.9993, and 0.9998 for DDSM, INbreast, MIAS, and mixed datasets, respectively. Moreover, the observed performance improvement using our method against the patch-based method was statistically significant, with a p-value of 0.0029. Furthermore, our patchless approach performed better than patch- and whole image-based methods, improving test accuracy by 8% (91.41% vs. 99.34%), tested on the INbreast dataset. The proposed method is of significant importance in solving the need for a large training dataset as well as reducing the computational burden in training and implementing the mammography-based deep-learning models for early diagnosis of breast cancer.
Breast cancer is the most common type of cancer and it is treated with surgical intervention, radiotherapy, chemotherapy, or a combination of these regimens. Despite chemotherapy’s ample use, it has limitations such as bioavailability, adverse side effects, high-dose requirements, low therapeutic indices, multiple drug resistance development, and non-specific targeting. Drug delivery vehicles or carriers, of which nanocarriers are prominent, have been introduced to overcome chemotherapy limitations. Nanocarriers have been preferentially used in breast cancer chemotherapy because of their role in protecting therapeutic agents from degradation, enabling efficient drug concentration in target cells or tissues, overcoming drug resistance, and their relatively small size. However, nanocarriers are affected by physiological barriers, bioavailability of transported drugs, and other factors. To resolve these issues, the use of external stimuli has been introduced, such as ultrasound, infrared light, thermal stimulation, microwaves, and X-rays. Recently, ultrasound-responsive nanocarriers have become popular because they are cost-effective, non-invasive, specific, tissue-penetrating, and deliver high drug concentrations to their target. In this paper, we review recent developments in ultrasound-guided nanocarriers for breast cancer chemotherapy, discuss the relevant challenges, and provide insights into future directions.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.